Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03069352 · ClinicalTrials.gov registry record · Phase 3
A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy
A Phase 3 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 3
- Development phase
- 211
- Enrollment target
NCT03069352 is a Phase 3 study that has completed, run by AbbVie. The registered enrollment target is 211 participants.
The verdict
NCT03069352, a Phase 3 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 211 participants
- Enrollment target
Study Summary
The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).
Interventions
- DRUG Venetoclax
- DRUG Placebo
- DRUG Cytarabine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 211 participants |
| Start Date | 2017-05-23 |
| Est. Completion | 2025-08-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03069352
The ClinicalTrials.gov registry entry for NCT03069352 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 211 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Venetoclax is the first listed.
NCT03069352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03069352 about?
NCT03069352 is a clinical study titled "A Study of Venetoclax in Combination With Low Dose Cytarabine Versus Low Dose Cytarabine Alone in Treatment Naive Patients With Acute Myeloid Leukemia Who Are Ineligible for Intensive Chemotherapy". The primary objective of this study is to evaluate if venetoclax when co administered with low-dose cytarabine (LDAC) improves overall survival (OS) versus LDAC and placebo, in treatment-naïve patients with acute myeloid leukemia (AML).
What is the current status of trial NCT03069352?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 211 participants. The study started on 2017-05-23. Estimated completion is 2025-08-21.
What interventions are being tested in trial NCT03069352?
The interventions under investigation include: Venetoclax (DRUG), Placebo (DRUG), Cytarabine (DRUG).
Who is sponsoring clinical trial NCT03069352?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.